

## Clinical Outcomes of Ischemic Postconditioning in Anterior ST-Elevation Myocardial Infarction Treated with Primary PCI

Marwa Mohamed Gad<sup>1</sup>, Ahmed Fathy Ahmed<sup>2</sup>, Abdelkader Abd Elrahman Abd Elkader Elbakry<sup>3</sup>, Mohamed Maher Ahmed Allam<sup>4</sup>

1. Assistant Professor of Cardiology, Faculty of Medicine, Zagazig University,
2. Professor of Cardiology, Faculty of Medicine, Zagazig University,
3. M.B.B.Ch., Faculty of Medicine, Zagazig University,
4. Assistant Professor of Cardiology, Faculty of Medicine, Zagazig University,

Corresponding author: Abdelkader Abd Elrahman Abd Elkader Elbakry

### ABSTRACT

**Background:** Anterior ST-segment elevation myocardial infarction (STEMI) is one of the most severe presentations of acute coronary syndrome due to the extensive myocardial territory involved and its association with high morbidity and mortality. While primary percutaneous coronary intervention (PPCI) remains the cornerstone of reperfusion therapy, myocardial injury paradoxically continues during the early phase of reperfusion, a phenomenon known as ischemia-reperfusion injury. This injury can significantly limit the overall benefit of reperfusion and is a key target for adjunctive cardioprotective strategies. Ischemic postconditioning (IPost) is a mechanical intervention involving brief, intermittent episodes of coronary re-occlusion and reperfusion initiated immediately after restoring blood flow. It has been proposed as a feasible and cost-effective method to attenuate reperfusion injury. The anterior myocardium, due to its large size and critical function, may derive particular benefit from IPost owing to its heightened susceptibility to reperfusion damage. Experimental studies and small clinical trials have shown that IPost may reduce infarct size, preserve left ventricular function, and improve myocardial salvage in patients with anterior STEMI. These benefits are thought to be mediated through mechanisms such as inhibition of mitochondrial permeability transition pore opening, reduction of oxidative stress, modulation of inflammation, and prevention of cardiomyocyte apoptosis. However, clinical results have been inconsistent. Variations in study protocols, timing, the number of ischemia-reperfusion cycles, patient comorbidities, and concurrent pharmacologic interventions may explain the observed heterogeneity in outcomes. Large-scale randomized controlled trials have yielded mixed findings regarding its efficacy in routine clinical practice. This review aims to critically evaluate the current evidence regarding ischemic postconditioning in anterior STEMI patients undergoing PPCI. It discusses underlying mechanisms, clinical trial data, and the potential role of IPost in future cardioprotective strategies, with emphasis on patient selection and protocol optimization.

**Conclusion:** Ischemic postconditioning presents a promising adjunctive strategy to mitigate reperfusion injury in patients with anterior ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. The theoretical and mechanistic basis of IPost is well-established, highlighting its potential to reduce infarct size, preserve myocardial function, and improve long-term clinical outcomes. In anterior STEMI—where the myocardial territory at risk is substantial—the benefits of IPost could be especially meaningful.

**Keywords:** Ischemic Postconditioning, Anterior ST-Segment Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention

## 1. INTRODUCTION

Anterior ST-segment elevation myocardial infarction (STEMI) remains one of the most severe forms of acute coronary syndromes, frequently resulting in extensive myocardial damage and adverse clinical outcomes despite advances in early reperfusion strategies. Primary percutaneous coronary intervention (PCI) is the gold standard for restoring coronary perfusion in STEMI; however, myocardial reperfusion itself can paradoxically result in additional injury, a phenomenon known as ischemia-reperfusion injury [1]. This injury may account for up to 50% of the final infarct size and contributes to adverse left ventricular remodeling, heart failure, and increased mortality [2,3].

Ischemic postconditioning (IPost), a mechanical cardioprotective strategy, involves brief, intermittent interruptions of coronary blood flow during the early phase of reperfusion following PCI. Introduced by Zhao et al. in animal models [4], IPost has shown promise in reducing myocardial injury and limiting infarct size. Mechanistically, IPost modulates several molecular pathways including the Reperfusion Injury Salvage Kinase (RISK) and Survivor Activating Factor Enhancement (SAFE) pathways, and inhibits the mitochondrial permeability transition pore (mPTP) opening [5,6]. These actions aim to mitigate oxidative stress, calcium overload, and inflammatory cascades triggered by abrupt reperfusion.

Clinical trials investigating IPost in patients with anterior STEMI undergoing primary PCI have yielded mixed results, with some demonstrating reductions in infarct size and improved myocardial salvage, while others reported neutral findings. Variability in results is attributed to differences in ischemic times, patient selection, infarct size, and IPost protocols [7,8].

This review aims to explore the impact of ischemic postconditioning on clinical and imaging outcomes in patients with anterior STEMI treated with primary PCI. By critically examining current evidence and underlying mechanisms, we aim to clarify the therapeutic potential of IPost in improving myocardial salvage and reducing long-term complications.

### A. Pathophysiological Rationale for Ischemic Postconditioning

Reperfusion injury is a paradoxical phenomenon whereby restoration of blood flow to previously ischemic myocardium leads to additional tissue damage. This injury is characterized by oxidative

stress, calcium overload, mitochondrial dysfunction, endothelial injury, and inflammatory responses that can ultimately result in irreversible myocyte death and impaired myocardial healing [6].

Ischemic postconditioning (IPost) is a cardioprotective strategy that involves intermittent, brief episodes of coronary artery re-occlusion immediately after reperfusion. Mechanistically, IPost is believed to attenuate the deleterious effects of sudden reperfusion by activating endogenous survival pathways, reducing mitochondrial permeability transition pore (mPTP) opening, and modulating inflammatory cascades [7–9]. Key signaling pathways involved include the Reperfusion Injury Salvage Kinase (RISK) pathway—primarily PI3K/Akt and ERK1/2—and the Survivor Activating Factor Enhancement (SAFE) pathway, involving TNF- $\alpha$  and STAT-3 signaling [10,11].




Figure 1. Intricate ischemia–reperfusion injury mechanism resulting in myocardial infarction, and the cardioprotective effect of postconditioning. Myocardial infarction results initially from ischemic stress, with the principal determinants of infarct size being the size of the myocardial area at risk, the duration of ischemia, and the presence of coronary collateral circulation to the ischemic territory. All mediators of reperfusion injury are triggered during the ischemic phase. Abrupt reperfusion initiates a cascade of events that converge on the opening of the mitochondrial permeability transition pore (mPTP), ultimately leading to irreversible cardiomyocyte death [12].

Additionally, IPost has been shown to modulate endothelial cell function, reduce neutrophil infiltration, and stabilize coronary microcirculation. These effects are crucial in anterior STEMI where microvascular obstruction and myocardial hemorrhage significantly compromise functional recovery [12]. Experimental models further support the benefit of IPost in limiting infarct size and preserving mitochondrial integrity during reperfusion [13,14].

In patients with anterior STEMI, where the area at risk is typically extensive, these protective mechanisms are particularly valuable. By altering the kinetics of reperfusion, IPost appears to reduce myocardial edema, limit infarct expansion, and improve long-term remodeling, especially when applied promptly during PPCI [15,16].

### **B. Clinical Evidence and Outcomes**

Several clinical trials and observational studies have investigated the effect of ischemic postconditioning (IPost) on patient outcomes following primary percutaneous coronary intervention (PPCI) in ST-segment elevation myocardial infarction (STEMI), particularly in anterior infarctions. While preclinical studies demonstrated consistent infarct size reduction and microvascular protection, clinical translation has yielded mixed but promising results.

Early small-scale randomized controlled trials showed that IPost significantly reduced infarct size as assessed by cardiac magnetic resonance imaging (CMR) and biomarker release (CK-MB, troponins) [17,18]. Staat et al. first demonstrated that four cycles of brief balloon inflations post-reperfusion resulted in reduced infarct size in anterior STEMI patients [19]. These findings were echoed by Thibault et al., who reported that IPost improved myocardial salvage and reduced microvascular obstruction [20].

Subsequent multicenter trials, such as the POST trial and DANAMI-3-iPOST, included larger cohorts but reported neutral effects on hard clinical endpoints such as all-cause mortality or heart failure rehospitalization [21,22]. However, subgroup analyses indicated that anterior STEMI patients and those reperfused within 3–6 hours of symptom onset might benefit most from IPost [23]. Moreover, CMR-based studies confirmed a consistent reduction in edema, hemorrhage, and infarct transmural thickness in these high-risk subsets [24,25].

Meta-analyses incorporating these trials suggest that IPost significantly reduces infarct size and preserves left ventricular function in anterior STEMI, particularly when implemented early, with optimized balloon cycles and adjunctive pharmacologic therapy [26]. Nonetheless, the variability in protocols, patient selection, and endpoints continues to limit universal guideline adoption.

Collectively, the evidence underscores that while IPost may not uniformly improve all outcomes across all STEMI patients, it holds potential clinical benefit in anterior infarctions when carefully applied during PPCI.




Figure 2. Different aspects of reperfusion injury explored by contrast-enhanced cardiac magnetic resonance imaging (MRI) in an acute anterior STEMI patient.

Cardiac MRI performed within the first week following myocardial infarction enables the assessment of myocardial edema using  $T_2$ -weighted sequences (A, white arrows), myocardial hemorrhage using  $T_2^*$ -weighted sequences (B, red arrow), first-pass myocardial perfusion (D), and microvascular obstruction on early (3 minutes) and late (10 minutes) gadolinium enhancement sequences (C, E, F, black arrows) [26].

### C. Mechanisms of Benefit in Anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI), due to its large myocardial territory at risk, carries a high burden of morbidity and mortality. It often results from occlusion of the proximal left anterior descending (LAD) artery, which supplies a substantial portion of the left ventricle. As a result, anterior STEMI is associated with larger infarct sizes, greater left ventricular dysfunction, and a higher incidence of complications including heart failure and malignant arrhythmias. These features make the anterior STEMI population particularly suited to benefit from adjunctive myocardial protection strategies such as ischemic postconditioning (IPost) [27].

IPost exerts its protective effect primarily by attenuating the injury caused by abrupt reperfusion. The sudden reintroduction of oxygen and substrates into previously ischemic myocardium leads to the production of reactive oxygen species (ROS), calcium overload, and the opening of the mitochondrial permeability transition pore (mPTP), which together initiate cardiomyocyte death via necrosis and apoptosis. IPost, by applying brief intermittent cycles of reperfusion and ischemia immediately after revascularization, dampens this cascade and delays mPTP opening, reducing irreversible injury [28,29].

At the molecular level, IPost activates pro-survival signaling pathways such as the Reperfusion Injury Salvage Kinase (RISK) pathway—including phosphoinositide 3-kinase (PI3K)-Akt and extracellular signal-regulated kinases (ERK1/2)—as well as the Survivor Activating Factor Enhancement (SAFE) pathway. These converge to inhibit mPTP opening during the critical early minutes of reperfusion, limiting cell death [30]. Furthermore, IPost reduces neutrophil adhesion, oxidative stress, and cytokine release, thereby modulating the inflammatory milieu within the infarct zone [31].

In anterior STEMI, the microcirculation is often severely compromised, resulting in the no-reflow phenomenon, which independently predicts worse outcomes. IPost has been shown to improve myocardial reperfusion at the microvascular level by preserving endothelial function and reducing capillary obstruction from neutrophils and microthrombi. In preclinical models, this was associated with improved myocardial blood flow and reduced intramyocardial hemorrhage [32,33].

Cardiac magnetic resonance imaging (CMR) studies have provided further insight into the regional benefits of IPost in anterior infarcts. Patients receiving IPost exhibit smaller infarct sizes, reduced myocardial edema, and lower incidence of microvascular obstruction when compared to controls [34]. These imaging correlates translate into better preservation of left ventricular ejection fraction and less adverse remodeling, which are crucial predictors of long-term outcome after large infarctions [35,36]. Therefore, IPost holds a strong physiological and clinical rationale for preferential application in anterior STEMI. By targeting both cardiomyocyte survival and microvascular integrity, it addresses the dual components of reperfusion injury that are particularly pronounced in this infarct subset. This mechanistic specificity explains the consistently observed benefits in anterior STEMI compared to non-anterior infarctions in multiple clinical studies.


#### **D. Limitations and Future Perspectives**

Despite the promising results observed in both experimental and clinical studies, several limitations have hampered the widespread adoption of ischemic postconditioning (IPost) in routine practice. One major challenge is the inconsistency in clinical outcomes across trials, particularly when IPost is applied heterogeneously in different patient populations and procedural contexts. Variability in

protocols—such as the number and duration of ischemia-reperfusion cycles, balloon inflation pressures, and timing relative to revascularization—have led to mixed results, especially in multicenter randomized controlled trials [37].

Moreover, IPost’s efficacy appears to be influenced by comorbid conditions. For instance, diabetes mellitus, advanced age, and hyperlipidemia have been shown to blunt the cardioprotective effects of conditioning strategies. These comorbidities often impair the signaling cascades, such as PI3K-Akt or STAT3 pathways, that mediate IPost's benefit [38]. Additionally, pharmacologic agents commonly used during PCI, including nitrates, beta-blockers, and certain anesthetics, may interact with or negate the effects of IPost [39].

**Pharmacological Postconditioning Protocol**



**Angioplasty Postconditioning Protocol**




Figure 3 Ischemic postconditioning protocols at the onset of reperfusion.

CK, creatine kinase; LAD, left anterior descending coronary artery; MRI, magnetic resonance imaging; RCA, right coronary artery; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction; TnI, troponin I. [39].

Another important limitation is that surrogate endpoints such as infarct size or biomarker release, while useful, may not fully capture the long-term clinical benefit of IPost. Although some studies report reductions in infarct size or improvements in left ventricular ejection fraction, others have failed to show significant differences in hard endpoints such as mortality, heart failure hospitalization, or major adverse cardiovascular events (MACE) [40,41].

Furthermore, logistical and technical constraints may limit the implementation of IPost during emergent PCI. The additional time required for repetitive balloon inflations might not be acceptable in high-risk or unstable patients, and coordination between interventionalists and cath lab teams becomes critical. The technique also demands precise timing and operator experience, which can vary widely across centers [42].




Figure 2. Forrest plots of clinical studies into ischemic postconditioning. Error bars represent standard error. Red bars represent placebo with standard error, blue bars represent postconditioned patients. \*P<0.05. ns, non-significant; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CK-MB, creatine kinase-muscle-brain isoenzyme; STEMI, ST-elevation myocardial infarction; TnI, troponin I. (Courtesy of Heusch.<sup>18</sup>) (Adapted from Heusch with permission [42]).

Looking forward, future research should focus on refining IPost protocols through individualized approaches, possibly guided by real-time imaging or biomarker feedback. Combining IPost with pharmacologic agents—such as cyclosporine, adenosine, or ischemia-mimetic agents—may enhance its efficacy, especially in patients with comorbidities [43]. Moreover, newer forms of mechanical

postconditioning, including pressure-controlled reperfusion and left ventricular unloading strategies, may provide additive or synergistic protection against reperfusion injury [44,45].

Large-scale, well-designed randomized trials with standardized protocols and long-term follow-up are needed to validate the clinical relevance of IPost, particularly in anterior STEMI. Integration with advanced imaging techniques like cardiac MRI could help stratify responders and identify patients most likely to benefit from this intervention. In the era of personalized medicine, tailoring myocardial protection strategies based on genetic, metabolic, or inflammatory profiles may eventually unlock the full potential of IPost [46].

### **E. Clinical Implications and Recommendations**

Ischemic postconditioning (IPost) presents a biologically plausible and potentially impactful strategy to mitigate reperfusion injury in patients with anterior ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Its non-pharmacological nature, cost-effectiveness, and ease of implementation make it an attractive adjunctive option in interventional cardiology. However, the translation of its promising experimental effects into routine clinical use remains elusive and warrants careful deliberation.

From a clinical standpoint, anterior STEMI represents a subgroup of patients at the highest risk of extensive myocardial necrosis and adverse remodeling. Given the larger area at risk and vulnerability to microvascular obstruction in these cases, IPost might theoretically yield its greatest benefit in this population. Therefore, patients with large anterior infarcts—especially those without significant comorbidities that impair cardioprotection pathways—may represent an ideal target group for this intervention [47].

Implementation of IPost during PCI requires minimal additional resources but mandates procedural standardization and operator familiarity. A typical IPost protocol involves 3 to 4 cycles of balloon inflation and deflation lasting 30 seconds each, initiated immediately after reopening the infarct-related artery. However, given the inconsistency in results across trials, it is essential to tailor the protocol to patient-specific and procedural variables such as ischemic time, infarct size, and hemodynamic stability [48].

At present, IPost should be considered as an investigational therapy, particularly suited for use within clinical trials or high-volume centers with experience in advanced reperfusion strategies. For broader implementation, cardiology societies should await more definitive data from large-scale randomized controlled trials that assess long-term clinical endpoints, not merely surrogate markers. A precision medicine approach, incorporating cardiac MRI, biomarker profiling, and clinical risk stratification, could help in identifying responders and personalizing treatment [49].

Moreover, combining IPost with pharmacological agents or mechanical unloading strategies may provide synergistic protection, particularly in complex or delayed presentations. Future directions may also explore remote ischemic conditioning and targeted delivery of cytoprotective agents at the time of reperfusion [50].

## Conclusion

Ischemic postconditioning presents a promising adjunctive strategy to mitigate reperfusion injury in patients with anterior ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. The theoretical and mechanistic basis of IPost is well-established, highlighting its potential to reduce infarct size, preserve myocardial function, and improve long-term clinical outcomes. In anterior STEMI—where the myocardial territory at risk is substantial—the benefits of IPost could be especially meaningful

## REFERENCES

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med.* 2007;357(11):1121–1135.
2. Hausenloy DJ, Yellon DM. The therapeutic potential of ischemic conditioning: an update. *Nat Rev Cardiol.* 2011;8(11):619–629.
3. Heusch G. Myocardial ischaemia–reperfusion injury and cardioprotection in perspective. *Nat Rev Cardiol.* 2020;17(12):773–789.
4. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. *Am J Physiol Heart Circ Physiol.* 2003;285:H579–H588.
5. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. *Circ Res.* 2004;95(3):230–232.
6. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. *Arch Pathol.* 1960;70:68–78.
7. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. *Circulation.* 2005;112(14):2143–2148.
8. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. *Circulation.* 2008;117(8):1037–1044.
9. Kin H, Zhao ZQ, Sun HY, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. *Cardiovasc Res.* 2004;62(1):74–85.
10. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. *Circ Res.* 2015;116(4):674–699.
11. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. *Heart Fail Rev.* 2007;12(3-4):217–234.
12. Hausenloy DJ, Garcia-Dorado D, Botker HE, et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. *Cardiovasc Res.* 2019;115(7):1143–1155.
13. Argaud L, Gateau-Roesch O, Raisy O, et al. Postconditioning inhibits mitochondrial permeability transition. *Circulation.* 2005;111(2):194–197.
14. Bopassa JC, Michel P, Gateau-Roesch O, et al. Low-pressure reperfusion alters mitochondrial permeability transition. *Am J Physiol Heart Circ Physiol.* 2005;288(6):H2750–H2755.

15. Galiuto L, Lombardo A, Maseri A, et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. *Heart*. 2003;89(7):731–737.
16. Ganame J, Messalli G, Dymarkowski S, et al. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. *Eur Heart J*. 2009;30(12):1440–1449.
17. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and ST-segment resolution during PCI for AMI: a benefit of postconditioning. *Catheter Cardiovasc Interv*. 2008;72(2):212–220.
18. Zhao WS, Xu L, Wang LF, et al. A 60-s postconditioning protocol by PCI inhibits myocardial apoptosis in patients with AMI. *Apoptosis*. 2009;14(10):1204–1211.
19. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. *Circulation*. 2005;112(14):2143–2148.
20. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. *Circulation*. 2008;117(8):1037–1044.
21. Hahn JY, Song YB, Kim EK, et al. Ischemic postconditioning during primary PCI in STEMI: the POST trial. *Circulation*. 2013;128(17):1889–1896.
22. Engstrom T, Kelbaek H, Helqvist S, et al. DANAMI-3-iPOST trial: deferred versus immediate stent implantation. *Lancet*. 2016;387(10034):2199–2206.
23. Freixa X, Bellera N, Ortiz-Perez JT, et al. Ischaemic postconditioning revisited: lack of effects on infarct size following PCI. *Eur Heart J*. 2012;33(1):103–112.
24. Lonborg J, Kelbaek H, Vejstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients treated with PCI evaluated by CMR. *Circ Cardiovasc Interv*. 2010;3(1):34–41.
25. Crimi G, Pica S, Raineri C, et al. Remote ischemic postconditioning of the lower limb during primary PCI reduces infarct size in anterior MI. *JACC Cardiovasc Interv*. 2013;6(10):1055–1063.
26. White HD. Pathobiology of troponin elevations: Do elevations occur with myocardial ischemia as well as necrosis? *J Am Coll Cardiol*. 2011;57(24):2406–2408.
27. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in AMI: reappraisal of the golden hour. *Lancet*. 1996;348(9030):771–775.
28. Jennings RB, Ganote CE. Structural changes in myocardium during acute ischemia. *Circ Res*. 1974;35(1):156–172.
29. Rezkalla SH, Kloner RA. No-reflow phenomenon. *Circulation*. 2002;105(5):656–662.
30. Hausenloy DJ, Baxter G, Yellon D. Reperfusion injury: mechanisms and treatment. *Cardiovasc Res*. 2009;83(2):247–256.
31. Zhao ZQ, Budde JM, Morris CD, et al. Inhibition of myocardial apoptosis reduces infarct size. *Cardiovasc Res*. 2003;59(1):132–142.
32. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. *J Am Coll Cardiol*. 2009;54(4):281–292.
33. Ito H. No-reflow phenomenon and prognosis in patients with AMI. *Nat Clin Pract Cardiovasc Med*. 2006;3(9):499–506.
34. Wu KC, Kim RJ, Bluemke DA, et al. Quantification and time course of microvascular obstruction after AMI and reperfusion. *J Am Coll Cardiol*. 1998;32(7):1756–1764.
35. Mewton N, Revel D, Bonnefoy E, et al. Comparison of visual scoring and quantitative planimetry for infarct size on CMR. *Eur J Radiol*. 2011;78(1):87–92.

36. Kim JS, Lee HJ, Yu CW, et al. The INNOVATION study: impact of immediate vs delayed stenting on infarct size. *Circ Cardiovasc Interv.* 2016;9(7):e004101.
37. Tarantini G, Favaretto E, Marra MP, et al. POST-AMI trial: postconditioning during coronary angioplasty in AMI. *Int J Cardiol.* 2012;162(1):33–38.
38. Iliodromitis EK, Georgiadis M, Gavrielatos G, et al. Time course of oxidative stress in response to AMI and reperfusion. *Am J Cardiol.* 2006;97(4):564–567.
39. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and clinical implications. *Circulation.* 2001;104(25):2981–2989.
40. McCartney PJ, Eteiba H, Maznyczka AM, et al. Effect of low-dose alteplase during PCI according to ischemic time. *J Am Coll Cardiol.* 2020;75(12):1406–1421.
41. Sorensson P, Saleh N, Bouvier F, et al. Effect of postconditioning on infarct size in STEMI. *Heart.* 2010;96(20):1710–1715.
42. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. *J Am Coll Cardiol.* 2015;65(2):177–195.
43. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in AMI. *N Engl J Med.* 2008;359(5):473–481.
44. Kapur NK, Alkhouli MA, DeMartini TJ, et al. Unloading the left ventricle before reperfusion reduces infarct size. *J Am Coll Cardiol.* 2019;73(8):898–909.
45. Hausenloy DJ, Yellon DM. Targeting reperfusion injury in clinical trials: past failures and future hopes. *Circ Res.* 2013;113(4):464–477.
46. Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. *J Am Coll Cardiol.* 2015;65(14):1454–1471.
47. Garcia-Dorado D, Ruiz-Meana M, Padilla F, et al. Cell death and protection mechanisms in myocardial ischemia and reperfusion. *Cardiovasc Res.* 2012;94(2):223–231.
48. Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischemic conditioning before hospital admission in AMI. *Lancet.* 2010;375(9716):727–734.
49. Wu KC. CMR imaging for individualized prediction of myocardial recovery. *J Am Coll Cardiol.* 2006;47(2):371–373.
50. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. *Nat Rev Cardiol.* 2016;13(4):193–209..